GET DAILY SIGNALSQuantum-Si (QSI): Can the Stock Reach the $2.30 Analyst Target?
Key Takeaways
- The $2.30 central target is the arithmetic mean of three verified, current analyst price targets: $4.00 (H.C. Wainwright), $1.90 (Alliance Global Partners), and $1.00 (Canaccord Genuity).
- With the latest verified price near $1.12, reaching $2.30 implies roughly 105% upside — a very large move by any standard.
- The analyst target range is extremely wide, from $1.00 to $4.00, reflecting deep disagreement about the company's commercial prospects.
- Key support comes from Proteus development milestones, a sizeable cash balance, and regained Nasdaq listing compliance.
- The biggest risks are shrinking revenue, heavy cash burn, potential dilution, and a history of falling below the $1.00 minimum bid price.
Analyst Price Targets and Consensus View
Three attributable analyst price targets form the basis of the $2.30 figure. H.C. Wainwright's Swayampakula Ramakanth reiterates a Buy with a $4.00 target, most recently reaffirmed in October 2026. Alliance Global Partners' Scott Henry maintains a Buy but lowered his target to $1.90 from $2.50 in August 2026 following the second-quarter report. Canaccord Genuity holds the most cautious stance, reiterating a Hold with a $1.00 target in May 2026.
That gives an approximate low-to-high range of $1.00 to $4.00 and a calculated mean of $2.30. The spread between the highest and lowest targets — a fourfold difference — is unusually large and signals genuine disagreement. Bulls argue the Proteus single-molecule platform can transform the business, while skeptics see a pre-revenue development story still struggling to gain commercial traction. The average should not be read as a guarantee; it is simply the midpoint of three very different views. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
QSI has traded with extreme volatility, recently around $1.12 after a sharp October rally to roughly $1.53 faded. The move from about $1.12 to $2.30 represents approximately 105% upside, which must be characterized as very large. The stock's own 52-week range illustrates the scale of the swings, spanning from below $0.70 to more than $3.00 at points.
For the target to be reached, the company would likely need to convert its technical milestones into demonstrable commercial progress. Quantum-Si expects to demonstrate detection of all 20 amino acids on Proteus by year-end, with the platform on a timeline for launch in 2027. A credible path toward the target hinges on investors repricing the shares from a speculative, pre-commercial valuation toward one that assumes a successful product launch and eventual revenue growth.
What Could Support a Move Toward the Target
The strongest catalyst is the Proteus development program. In October 2026 the company said it had demonstrated detection of 19 amino acids and was working to reach all 20, a key proof-of-concept for single-molecule protein sequencing. Partnerships with organizations including Cell Signaling Technology and Nvidia aim to validate the platform and strengthen its commercial positioning.
The balance sheet also provides a cushion. Quantum-Si reported roughly $190 million in cash, cash equivalents, and marketable securities at the end of the first quarter of 2026, funding it well beyond the near term. Regaining compliance with Nasdaq's minimum bid price requirement in October 2026 removed an immediate overhang and reduced forced-selling pressure. From what I see, this compliance step is important because it stabilizes the trading environment.
What Could Prevent the Target From Being Reached
The fundamental picture remains challenging. Revenue fell about 20% in 2025 to roughly $2.4 million, and first-quarter 2026 revenue of about $258,000 was down roughly 69% year over year as customers deferred purchases of the existing Platinum instruments ahead of Proteus. The company continues to post substantial net losses, on the order of $100 million annually, and management has acknowledged it may need additional equity or debt financing before revenue scales — a potential source of dilution.
Sentiment risk is also material. Some commentators note that QSI has at times been swept up in quantum-computing enthusiasm despite not being a quantum-computing company, a dynamic that can reverse quickly. The stock has twice fallen below the $1.00 Nasdaq minimum bid threshold in under two years, underscoring the downside volatility inherent in the name.
Technical Levels and Market Structure
The $1.00 level is the single most important technical and psychological mark, serving as both the Nasdaq minimum bid threshold and a key support and resistance zone. Below that sits the 52-week low near $0.69. On the upside, the shares would need to reclaim and hold levels well above $1.50 — the recent October spike high — before the $2.30 target becomes relevant. The stock's beta of roughly 3 indicates it is considerably more volatile than the broader market, amplifying both rallies and selloffs. I'm watching this closely as volatility often creates both opportunity and risk in names like this.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of around 12 months, though individual assumptions vary. H.C. Wainwright's $4.00 target implies a successful Proteus launch and meaningful adoption, while Canaccord's $1.00 target reflects persistent doubts about commercial traction within that window. Investors should watch the November 2026 business update and third-quarter results, any confirmation of the all-20 amino acid milestone, the Proteus launch timeline, revenue trends, cash burn, and any financing announcements. Revisions to analyst targets and Nasdaq listing status also matter.
Integrating AI Daily Buy/Sell Signals Into Analysis
In my research process I occasionally reference Tickeron’s AI Daily Buy/Sell Signals to cross-check momentum shifts on volatile holdings. The tool applies AI to monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on technical behavior and market conditions. For a name like QSI, this kind of data-driven view can help highlight when trends are shifting without relying solely on manual chart review.
Final Assessment
The $2.30 target is a calculated average of three widely divergent analyst views, not a forecast, and reaching it from roughly $1.12 would require a very large gain of about 105%. Supporting the case are the Proteus milestones, a healthy cash position, and restored Nasdaq compliance; working against it are contracting revenue, sustained losses, dilution risk, and a speculative trading profile. With a target range stretching from $1.00 to $4.00, the honest conclusion is that the market itself has not settled on QSI's true value. The November 2026 update and subsequent Proteus progress will likely determine whether the optimistic end of that range remains realistic.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
QSI's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Indicator for QSI moved out of overbought territory on October 12, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 instances where the indicator moved out of the overbought zone. In 24 of the 26 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 50 cases where QSI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
The Momentum Indicator moved below the 0 level on October 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QSI as a result. In 86 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for QSI turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 40 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
QSI broke above its upper Bollinger Band on September 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
QSI moved above its 50-day moving average on September 24, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for QSI crossed bullishly above the 50-day moving average on September 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +44.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where QSI advanced for three days, in 156 of 197 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 94 of 122 cases where QSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.360) is normal, around the industry mean (2.949). P/E Ratio (-2.435) is within average values for comparable stocks, (2.438). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (100.000) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. QSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement